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Open Access Letter to the editor
How long should Adjuvant Chemotherapy be given in Early Stage Colon 
Cancer?
Michael Retsky*
Harvard School of Public Health, Boston. MA 02115, USA
Abstract
After diagnosis of colon cancer, the tumor is removed and the stage of the disease is provided by a pathologist.   
If the stage indicates relatively high risk of relapse, adjuvant chemotherapy is used for 6 or so months to reduce the 
probability of such relapse. This is a very common situation in oncology – used for many early stage colon cancer 
patients of whom there will be 143,000 in 2013 in US. This therapy is only partially effective since 52,000 patients will 
die of metastatic colon cancer in 2013. Despite being used for decades, there is much room for improvement.
*Corresponding  author:  Michael  Retsky,  Harvard  School  of  Public  Health, 
Boston. MA 02115, USA, E-mail: michael.retsky@gmail.com 
Received March 01, 2013; Accepted April 22, 2013; Published April 24, 2013
Citation: Retsky M (2013) How long should Adjuvant Chemotherapy be given 
in  Early  Stage  Colon  Cancer?  J  Clin  Exp  Pathol  3:  136.  doi:10.4172/2161-
0681.1000136
Copyright: © 2013 Retsky M. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
In May 2011, I published an editorial discussing my personal use 
of low dose, long term adjuvant chemotherapy for stage IIIc colon 
cancer in 1994-1997[1]. This therapy became known as metronomic 
chemotherapy. The question I now raise is: generally speaking, how 
long should adjuvant chemotherapy be used? I came to the following 
conclusion  in  1994:  If  we  assume  first  that  cancer  growth  is  well 
behaved, i.e., all cancer cells in the tumor divide once and only once 
during  a  doubling  time,  and  second  that  the  chemotherapy  drug 
used is 100% effective, i.e., it kills every cell that tries to divide, then 
therapy duration should be one doubling time. Colon cancer volume 
doubling time is 2-3 months.  Based on my estimates in 1994 of tumor 
behavior  and  drug  5-FU  (5-Fluorouracil)  effectiveness,  I  calculated 
chemotherapy  should  ideally  be  used  longer  than  2  years.  Nobody 
could tolerate a toxic protocol for 2 years or more. Therefore, I used low 
dose infusional 5-FU therapy at a non-toxic level for 2.5 years. Thus this 
simple reasoning results in the conclusion that in order to be effective 
for all or nearly all cases, adjuvant chemotherapy for early stage colon 
cancer must be essentially nontoxic and used for over 2 years. 
Introduction
Winquist and Boucher describe the lack of innovative new paths 
moving forward in cancer therapeutics as bleak with improvements 
often  measured  in  months  [2].  Given  that  143,000  persons  will  be 
diagnosed and 52,000 patients will die of colon cancer in 2013 in the 
US, it is quite reasonable and appropriate to reconsider therapeutic 
concepts established long ago for the cancer treatment paradigm. In 
particular I will discuss here a reexamination of a long ago determined 
cancer therapeutic notion, i.e., the intensity and optimal duration of 
adjuvant chemotherapy after detection of early stage colon cancer. 
As is the practice, after colon cancer is detected and diagnosed 
following screening colonoscopy, the patient is sent to a surgeon who 
removes the tumor and who then sends tissue removed to the pathology 
department. The pathologist examines the specimen and provides a 
report describing many details and listing the stage of the cancer. The 
report will particularly indicate the depth of penetration of the tumor 
into or through the bowel wall and how many relevant lymph nodes 
are found to contain cancer cells. Protein expressions that are known 
to have prognostic implications are also reported. 
This information is then used by the medical oncologist who is the 
next physician in the treatment sequence. Given the patient’s overall 
health and stage, a treatment is recommended that has been shown by 
clinical trial to reduce the probability of metastatic relapse for that stage 
colon cancer. Some patients will be cured by the simple removal of the 
primary tumor. Others will relapse at some time in the next 6-8 years. 
In colon cancer, metastatic relapse is typically to the liver since there 
is a direct blood drain from the colon to the liver. Relapse usually, but 
not always these days, leads to eventual death from colon cancer and 
certainly is to be avoided if at all possible.
Stage II (basically node-negative) colon cancer is usually not given 
adjuvant therapy while stage III (node positive) colon cancer has higher 
risk of relapse and is usually given adjuvant therapy. The treatment 
meant to prevent relapse after surgical removal of the tumor is called 
surgical adjuvant therapy or simply adjuvant therapy. In the case of 
colon cancer, the mainstay therapy in 1994 when I was diagnosed with 
stage IIIc colon cancer was 5-flourouracil for 6 months. This might be 
given with leukovorin which seemed to improve response somewhat.   
Relapse  in  1994  virtually  always  led  to  death  from  the  disease. 
Fortunately this is not always the result in 2013.
Diagnosed  with  Stage  IIIC  Colon  Cancer  November 
1994
As a result of a routine physical exam in my early 50s, I had positive 
fecal occult blood tests twice which triggered colonoscopy in November 
1994. I was awake at the end of the colonoscopy and saw a big ugly 
tumor on the display. I knew exactly what it was. I did not have to wait 
for the GI doc to explain it to me or see a report from pathology. There 
was no uncertainty or anxiety.  While stage was yet unknown, I now 
had colon cancer.  I had no family history of colon cancer; my parents 
lived until their late 80s and early 90s and died of normal diseases of 
the elderly and particularly not cancer. My two brothers were healthy. I 
always tried to lead a healthy life style with reasonable diet and exercise. 
I was trim and in good condition.
Surgery was a month or so later and we subsequently found that the 
stage was unexpectedly high. The tumor had penetrated the muscularis 
propria and into the pericolonic fat. There were four nodes positive 
and p53 was mutated. It was relatively easy to look up the prognosis. It 
was not good. In absence of therapy there was 80% chance of relapse Citation: Retsky M (2013) How long should Adjuvant Chemotherapy be given in Early Stage Colon Cancer? J Clin Exp Pathol 3: 136. doi:10.4172/2161-
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and even with therapy there was still 50% chance of relapse. I had been 
doing research in breast cancer for a number of years and was on Judah 
Folkman’s staff at Harvard Medical School so knew much about tumor 
growth and the theoretical underpinnings and evidence for intensive 
short  course  adjuvant  chemotherapy.  I  knew  in  particular  that  the 
theory of using maximum tolerated drugs was based on the assumption 
that  cancer  growth  was  according  to  the  Gompertz  equation.  This 
meant that tumor growth was fastest when the tumor was small and 
then growth gradually declined as the tumor enlarged. Thus therapy 
which was most effective when the cancer was rapidly growing should 
be given as soon as possible after diagnosis and surgery and at the 
highest tolerable level possible. After six or so months therapy ceases 
and we hope for the best.
The tumor growth theory was based on a study from the 1960s 
by Laird [3,4]. I had studied the Laird papers in depth and came to 
the conclusion that these papers were hopelessly flawed. There were 
serious mathematical errors and the whole study was based on only 
18 rodents and one rabbit. Because there were multiple species, Laird’s 
conclusion was that the Gompertzian growth was a valid description 
of tumor enlargement in general. The mathematical flaw would have 
been detected by any college level student of mathematics. The Laird 
studies have been cited by well over 600 papers in the cancer literature. 
I came to the conclusion that none of these cancer researchers actually 
critically examined the Laird papers. They just assumed that the study 
was correct since it was published and so often cited. Or perhaps they 
did not know enough about elementary mathematics to find the errors. 
It is remarkable that something so key to oncology has not been given 
better scrutiny. There was an op-ed discussion in the New York Times 
[5] a few months ago claiming that the study of mathematics should 
be cut from curriculums in biology and medicine as not necessary in 
these modern times. I thought just the opposite. Perhaps over a million 
persons have been given maximum tolerated chemotherapy based on 
the mathematically flawed Laird papers. 
Maximum tolerated chemotherapy also has links to key studies 
of  Skipper  and  Schabel  [6-8]  in  the  1960s  and  1970s.  Skipper  and 
Schabel experimented with a leukemia animal model where the tumor 
grew exponentially with 1 day doubling time. This was convenient 
for experimentalists since a tumor could grow from one cell to a one 
centimeter tumor in 30 doubling times or one month. Skipper and 
Schabel could cure their animals after cancer was implanted if and only 
if they eradicated every last cancer cell and this could only be done with 
maximum tolerated chemotherapy. Their papers were laced with terms 
like LD-50 and LD-90 to indicate that the therapy they were using was 
lethal to 50% or 90% of the animals. The animals that survived the 
therapy were cured of cancer. Their papers included references to the 
Laird papers and stated that tumor growth was Gompertzian. I recall 
reading a discussion in one of their papers where they ask the rhetorical 
question if tumor growth might not be Gompertzian. Their answer was 
that it was possible but so unlikely that it was not worth considering. 
Skipper and Schabel papers were hugely influential in cancer science. 
Their papers have been cited over 2000 times. I was confident the entire 
philosophy of using maximum tolerated chemotherapy to cure cancer 
was based on flawed studies with key links to Laird papers and Skipper 
and Schabel papers. I knew the weaknesses in this theory and when my 
turn came, I sought to have a therapy that was based on more sturdy 
scientific foundation.
Initial Use of Metronomic Chemotherapy
Once  I  had  made  the  decision  not  to  use  maximum  tolerated 
chemotherapy I still had to find a therapy. After very useful information 
from  Jack  Speer,  MD  of  Colorado  Springs,  who  was  a  co-author 
of several papers with me, I contacted a few doctors in Eastern US 
where I then and still live. I was particularly impressed with William 
Hrushesky, MD who was at the time at a VA hospital in Albany, NY. 
Both Drs. Speer and Hrushesky had used infusional 5-FU for treatment 
of advanced colon cancer with some success in stabilizing the disease. I 
read everything available on the subject and eventually chose to use Dr. 
Hrushesky as the medical oncologist to design the therapy.
The therapy Dr. Hrushesky recommended was low dose infusional 
5-FU.  The  dosage  was  30%  reduction  from  the  usually  long  term 
tolerable level of 300 mg/meter-squared/day. Dr. Hrushesky was and 
still is very involved in the idea that chemotherapy should be given 
chrono-modulated, that is, during certain times of the day. He put me 
on a late afternoon to early evening schedule but I soon discovered that 
this was not going to work long term. As one example, I would go to 
a movie theater; while sitting in a quiet audience, every 90 seconds the 
pump would make an audible whirring noise. I read some papers and 
went to several conferences and found there was some disagreement 
on the exact best time of day to use chronomodulated chemotherapy.
I ended up using it when I went to bed at night and disconnecting 
in the morning. That made it much easier. I was on this therapy for 
about a year and was using 5 biomarkers to detect any early evidence 
of  a  relapse.  There  was  no  indication  of  impending  relapse.  I  was 
confident the therapy was either killing the cancer cells, stabilizing the 
disease or there were no metastatic cancer cells in the liver to begin 
with. The situation was at least stable and I had to decide on how long 
to continue. At this point, the therapy was quite tolerable and I could 
stay on as long as necessary. However I needed a reasonable goal.
Giving it some thought, I arrived at a simple answer.  Let’s assume 
the tumor cells behaved like soldiers in a parade – each cell dividing 
once and only once in each volume doubling time. This would be a 
well behaved tumor. Now let’s also assume the drug is perfect. That is 
while I am on 5-FU, any cancer cell that tries to divide will be killed. 
Under these ideal conditions, a well behaved tumor and a perfect drug, 
how long should chemotherapy be used? The answer is one volume 
doubling time which in the case of metastatic colon cancer is 2 or 3 
months. I then derived a simple algebraic expression to allow me to 
calculate what would be the result of a less than perfect drug and/or a 
less than well behaved tumor. I had to make some reasonable estimates 
but if I wanted to be reasonably sure that the therapy worked, I arrived 
at the result that the therapy must be longer than 2 years.
This puts clear limits on how tolerable the therapy has to be. I 
seriously doubt many patients could tolerate a toxic therapy for two 
years. The therapy therefore must be essentially non-toxic. The simple 
conclusion is that in order to prevent all or almost all relapses in early 
stage colon cancer, the therapy must be given over 2 years and must 
therefore be non-toxic. I used low dose infusional 5-FU for 2.5 years.   
There was virtually no toxicity. My finger tips were soft and somewhat 
numb, there were minor cracks in the skin where my fingers flexed 
and I had one or two blood blisters in my mouth. My fingernails grew 
in coarsely but nothing else happened. I did not miss a day of work, 
vomited, or was in any discomfort. I exercised every day and felt fine. 
I was on the staff of the late Judah Folkman while I was taking 
this  low  dose  infusional  5-FU.  I  discussed  my  therapy  with  Dr. 
Folkman towards the end of the therapy in 1996 or 1997. Based on 
information from Dr. Speer and Dr. Hrushesky, it was apparent that 
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to think that perhaps the drug given in that way might have been at 
least partially antiangiogenic. At that time it was well recognized that 
chemotherapy  drugs  worked  for  a  while  and  then  seemed  to  stop 
working. This was inelegantly termed “drug resistance”. It was also 
thought  that  antiangiogenic  drugs  did  not  develop  drug  resistance 
since the target vasculature was thought to have a stable genome as it 
was not malignant. Why then did low dose infusional 5-FU continue 
to work and not display drug resistance? I asked Judah Folkman if they 
ever tested low dose 5-FU for antiangiogenic properties. He brought 
Dr. Tim Browder into the room. Just the three of us were in the room. 
Browder had tested 5-FU and a number of other common cancer drugs 
for antiangiogenic properties but only given as bolus, never as I had 
used it. There was no indication of antiangiogenic activity. Folkman 
and Browder then decided that the therapy I was using should be 
tested for antiangiogenic action. It took about a year for this to happen. 
Browder had to implant special micro-pumps with 5-FU into tumor 
bearing mice. To great surprise it was partially antiangiogenic. Several 
other drugs were also antiangiogenic if given at low dose more or less 
continually. This was so unexpected that Browder had much difficulty 
getting a paper accepted stating these findings. Finally in April 2000 
a paper was accepted and published in Cancer Research [9]. I was 
not listed as an author. Dr. Folkman however had me talk to Robert 
Cooke who was writing a biography of Dr. Folkman [10]. There are 
three pages in Cooke’s book on my disease and therapy. Also Folkman 
introduced me on several occasions as the first human to use what was 
now called metronomic chemotherapy.
After  I  was  off  the  therapy  and  was  reasonably  confident  that 
it worked, I was very anxious to get the idea tested in a pilot study. 
Finally after asking Folkman for help in this, he took me to see the 
Medical head of Dan Farber Cancer Center. Thus I was in the Dana 
Farber chief’s office with Judah Folkman and went through the story. 
The Dana Farber doc finally said I was probably cured by surgery and 
the low dose infusional 5-FU did nothing. After that disappointing 
experience, I lost much interest in pursuing the idea. If I couldn’t get 
anything going with backing of Judah Folkman in front of the director 
of Dana Farber, who would do it? Another problem was that the drug 
was less expensive than sterile water so no pharmaceutical company 
would spend millions of dollars testing it if there was no financial 
reward at the end if it worked.
I  wrote  the  2011  editorial  in  frustration  that  the  therapy  was 
originally  used  in  1994  and  while  some  investigation  has  been 
conducted, it was now 17 years later and it still has not gotten properly 
tested  for  adjuvant  chemotherapy  for  early  stage  colon  cancer  as 
originally  designed  [11-14].  Now  2  years  later,  I  am  invited  to  a 
conference on treatment for metastatic colon cancer conducted by the 
Clinton Initiative - an influential organization. Maybe now something 
will  happen.  At  any  rate  this  document  will  describe  the  simple 
reasoning and requirements for adjuvant therapy to successfully treat 
stage IIIc colon cancer and perhaps the same logic applies to treatment 
of metastatic colon cancer. I was a participant on a cancer patient web 
site shortly after finishing therapy and found out that a patient with 
metastatic colon cancer used an almost identical therapy and her liver 
metastasis was completely eradicated. The patient was paraplegic and 
perhaps her physician decided she couldn’t take a toxic therapy and 
thus he used low dose infusional 5-FU which couldn’t hurt and might 
help.  I  reviewed  her  complete  medical  records  and  confirmed  that 
low dose infusional 5-FU was the only therapy she had and metastatic 
hepatic tumors were eradicated. I lost touch with this person but have 
her records somewhere in my files if anybody wants to see them.
Judah Folkman and Tim Browder are both deceased since 2008 so 
I am the person left alive who can tell the story about the origins of 
metronomic chemotherapy and the reasoning underlying it. 
Given this information and taking into consideration the scientific 
progress since 1994, how might we move forward?  Recent studies 
have pointed out that colon cancer is a complex heterogeneous disease, 
developing  through  multiple  genetic  and  epigenetic  abnormalities, 
such  as  defective  DNA  Mismatch  Repair  (dMMR)  and  the  CpG 
island  Methylator  Phenotype  (CIMP)  [15,16].  Adjuvant  therapy  is 
usually given to stage III patients but benefit to stage II colon cancer 
is debatable. Perhaps stage II would be a proper category to consider. 
Incidence of stage II colon cancer is 30-40% of all cases and relapse 
rate is approximately 15%. The incidence will increase as screening 
programs are implemented. For most patients with stage II disease, 
who are classified as standard risk, there are no known markers to 
refine risk assessment or to predict adjuvant chemotherapy benefit. 
Recently Donada et al. suggested the use of molecular markers, such 
as TYMS and CIMP-High status to select high risk patients with stage 
II colon cancer who may benefit from adjuvant 5-FU therapy [17]. 
Given these findings, it might make sense to consider a clinical trial of 
high risk stage II colon cancer patients comparing metronomic with 
conventional 5-FU chemotherapy. If this is progressing favorably a 
similar trial for stage III might be reasonable. 
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